• GlycoRNA–RBP Domains on the Cell Surface

  2026-08-14

  The reference preprint reports that cell-surface RNA-binding proteins and glycoRNAs assemble into nanoclusters that support entry of the cell-penetrating peptide TAT. Its perturbation experiments connect extracellular RNA, surface organization, and peptide internalization, expanding models of how the plasma membrane communicates with the extracellular environment.

• Influenza Hemagglutinin (HA) Peptide for IDH1 Studies

  2026-08-14

  Use this high-purity HA tag peptide to recover HA-fusion proteins under gentle, antibody-compatible conditions and to compare IDH1 variants in interaction and purification assays. The workflow connects competitive HA elution with the reference study’s chemoproteomic investigation of IDH1-R132H autopalmitoylation while clearly separating affinity purification from lipid-modification measurement.

• (R)-MG132 in Proteasome Mechanism Studies

  2026-08-13

  (R)-MG132 is a functionally inactive MG-132 enantiomer that strengthens proteasome inhibition validation. This article explains how to use it as a causal control when studying HNRNPU lactylation, PHGDH regulation, and cancer metabolism.

• Oseltamivir acid: Applied Research Workflows

  2026-08-13

  Oseltamivir acid supports a practical workflow that connects neuraminidase inhibition with influenza virus replication inhibition, resistance profiling, and exploratory oncology assays. This guide covers formulation, infection-model design, combination testing, translational interpretation, and troubleshooting for reproducible influenza antiviral research.

• G-1: Selective GPR30 Agonist Workflows

  2026-08-12

  G-1 enables controlled activation of GPR30/GPER1 in calcium, migration, cardiovascular, and spinal-neuron assays. This workflow-focused guide connects receptor pharmacology with practical dosing, controls, troubleshooting, and interpretation limits.

• Drug Response Metrics in Cancer In Vitro

  2026-08-12

  Hannah Schwartz’s dissertation separates relative viability from fractional viability to distinguish growth inhibition from actual cell killing. Its central implication is that anticancer responses should be interpreted across both dimensions and across time, rather than treating a single viability measurement as a complete description of drug activity.

• Z-DEVD-FMK in DR5 Apoptosis Assays

  2026-08-11

  Z-DEVD-FMK is more than a caspase-3 inhibitor: its activity across executioner caspases and calpain creates a powerful, but nuanced, perturbation tool. This article shows how to apply it to DR5–PD-L1 apoptosis assays without confusing pathway blockade with mechanistic proof.

• Cabozantinib (XL184) in RCC Signaling Research

  2026-08-11

  Cabozantinib, also called XL184, is a multi-target receptor tyrosine kinase inhibitor with VEGFR2, MET, RET, and AXL activity. Evidence from kinase assays, tumor models, and renal cell carcinoma phosphoproteomics supports its use for studying angiogenesis, tumor signaling, and chronic drug adaptation.

• Oseltamivir acid: Influenza Research Workflows

  2026-08-10

  Build reproducible neuraminidase, viral replication, and oncology assays with Oseltamivir acid, while controlling solubility, vehicle effects, and resistance-related variability. This guide translates product-specific evidence and a humanized-mouse pharmacokinetic study into practical assay decisions for influenza antiviral research.

• ECL Chemiluminescent Substrate Detection Kit Guide

  2026-08-09

  The ECL Chemiluminescent Substrate Detection Kit (Enhanced) supports sensitive HRP-based western blot chemiluminescence detection when weak protein bands, background, or limited sample are concerns. It is intended primarily for HRP-mediated protein immunodetection and should not be assumed to perform equivalently with non-HRP labels, ELISA, tissue imaging, or other assay formats without local validation.

• Targeted mRNA Nanoparticles and BBB Repair After Stroke

  2026-08-08

  This ACS Nano study developed M2 microglia-targeting lipid nanoparticles that deliver interleukin-10 mRNA to ischemic brain tissue after stroke. In mouse models, the treatment reinforced anti-inflammatory microglial polarization, reduced blood–brain barrier disruption and neuronal apoptosis, and improved neurological outcomes, while suggesting a poststroke treatment window extending to at least 72 hours.

• Salmonella Haem, SirM, and Macrophage Phagocytosis

  2026-08-07

  A recent Nature Microbiology study identifies SirM as a Salmonella methyltransferase that modifies HemL, increases bacterial haem synthesis, and suppresses macrophage phagocytosis through a TLR4-dependent effect on Cdc42. The work reframes pathogen-derived haem as an active immune-evasion factor, not merely an iron source, and connects this mechanism to macrophage death, mouse virulence, and competition with intestinal commensals.

• Anlotinib Hydrochloride: Next-Gen Anti-Angiogenic Strategies

  2026-08-07

  Explore the mechanistic depth and translational promise of Anlotinib hydrochloride, a multi-target tyrosine kinase inhibitor that redefines anti-angiogenic research. From endothelial cell migration inhibition to robust in vivo activity, this article delivers actionable insights, protocol guidance, and a strategic vision for cancer researchers seeking to bridge lab discoveries with clinical impact.

• Firefly Luciferase mRNA (5-moUTP): Innovations in Reporter G

  2026-08-06

  Explore how Firefly Luciferase mRNA (5-moUTP) optimizes bioluminescent reporter gene assays by integrating next-generation modifications for stability, immunogenicity, and translational efficiency. This article reveals pivotal scientific advances and practical guidance for maximizing assay reliability.

• Cyclic di-GMP: Applied Protocols for Biofilm & Immunity Rese

  2026-08-06

  Harnessing cyclic di-GMP as an intracellular second messenger unlocks novel methods for regulating biofilm persistence and activating innate immunity. Recent breakthroughs reveal its dual role as an antitoxin and STING pathway agonist, making it indispensable for both infection biology and cancer immunotherapy studies.

16913 records 1/1128 page Next 12345 下5页 Last page